6 August 2026

Kromek Group plc 

("Kromek" or the "Company" or the "Group") 

Delivery of third milestone under agreement with Siemens Healthineers

Grant of options to Directors

Kromek Group plc (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces the successful delivery of the third milestone under its enablement agreement (the "Enablement Agreement") with Siemens Medical Solutions USA, Inc. ("Siemens Healthineers") and the grant of options to directors of the Company.

Siemens Healthineers payment

Further to Kromek's announcement of 30 January 2025, the Company is pleased to announce that it has successfully delivered the third milestone under its Enablement Agreement with Siemens Healthineers and has received the third payment instalment of $2.5m. To date, the Company has received $32.5m under the Enablement Agreement. The remaining payment of $5.0m is payable at completion of the Group's delivery under the Enablement Agreement, which is expected to occur in the financial year to 30 April 2029.

Grant of options to directors

As detailed in the Company's final results announcement on 16 September 2025, Arnab Basu, CEO, and Berry Beumer, COO and President of the Advanced Imaging Division, were granted a special conditional bonus to be paid in four instalments dependent on the delivery of the four milestones under the Enablement Agreement, and the receipt by the Group of the associated cash payment, and subject to the individual remaining an employee of the Group. Dr. Basu and Mr. Beumer elected at that time to receive a significant proportion of the bonus as options over ordinary shares of 1p each ("Ordinary Shares") in the Company.

Accordingly, following the receipt of the third payment instalment under the Enablement Agreement, the Company granted, on 5 August 2026 (the "Grant Date"), Dr. Basu and Mr. Beumer 555,687 options each. The options vested upon issue and expire on the tenth anniversary of the Grant Date. The options have an exercise price of 1p per Ordinary Share and the number of options was calculated based on a price of 5.65p per Ordinary Share, being the average price of the Company's Ordinary Shares on AIM for the three months preceding and three months following the announcement of the Siemens Healthineers transaction on 30 January 2025.

Following this grant of options, the Company has options and long-term incentive awards outstanding over a total of 76,486,278 Ordinary Shares, representing 11.7% of the Company's issued share capital.

For further information, please contact: 

Engage with the Kromek management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our interactive investor
hub here: https://investors.kromek.com/

Subscribe to our news alert service: https://investors.kromek.com/auth/signup

Kromek Group plc 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them